Dr. Lawrence Fong, MD, is a leading figure in the field of cancer immunotherapy, renowned for his groundbreaking work in harnessing the immune system to fight cancer. He is a Professor of Medicine at the University of California, San Francisco (UCSF), where he holds the Efim Guzik Distinguished Professorship in Cancer Biology and leads the Cancer Immunotherapy Program. A board-certified medical oncologist, Dr. Fong earned his medical degree from Stanford University and completed his residency and fellowship training at UCSF. His career has been defined by a commitment to translating scientific discovery into transformative treatments for patients.
Dr. Fong is internationally known for his pioneering contributions to cancer vaccine and checkpoint blockade therapy development. His research focuses on understanding the mechanisms that determine whether immunotherapy will be effective for individual patients, with an emphasis on prostate, bladder, and kidney cancers. He has played a critical role in early-phase clinical trials and biomarker discovery, helping to establish foundational strategies that inform immunotherapy treatment protocols. His work is extensively published in leading scientific journals and has been integral to shaping the future of precision immuno-oncology.
In addition to his clinical and research achievements, Dr. Fong is a dedicated mentor and educator, training the next generation of physician-scientists in cancer immunotherapy. He is a frequent speaker at international oncology conferences and serves on advisory boards for major cancer research initiatives. Through his relentless pursuit of innovation and patient-centered research, Dr. Fong has helped redefine the landscape of cancer treatment, offering new hope through immune-based therapies that are changing lives worldwide.
Education
Medical School:
Stanford University School of Medicine
Residency:
Internal Medicine, University of Washington
Fellowship:
Medical Oncology, Stanford University School of Medicine
Board Certification:
Internal Medicine
Medical Oncology
Awards
- Bezos Distinguished Scholar, Fred Hutch
- National Cancer Institute Outstanding Investigator Award
- Earle Chiles Visiting Professorship
- V Foundation Scholar
- Alpha Omega Alpha
Memberships and affiliations
- Fred Hutch
- Journal of Immunotherapy of Cancer
- Society for Immunotherapy of Cancer
- Cancer Immunology Research
- American Society for Clinical Investigation
Research and publications
- Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus.
- Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
- Discovering dominant tumor immune archetypes in a pan-cancer census.
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
- Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
- CD4+ T cells in antitumor immunity.
- γδ T cells as critical anti-tumor immune effectors.
Other medical oncologist listed alphabetically, never by payment.
Browse all doctors →Open trials for these cancers, with the eligibility rules written in plain language.
Search trials →